These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 11159747)
1. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747 [TBL] [Abstract][Full Text] [Related]
2. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice. Hulla JE; French JE; Dunnick JK Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746 [TBL] [Abstract][Full Text] [Related]
3. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204 [TBL] [Abstract][Full Text] [Related]
4. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors. Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605 [TBL] [Abstract][Full Text] [Related]
5. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice. Dunnick JK; Hardisty JF; Herbert RA; Seely JC; Furedi-Machacek EM; Foley JF; Lacks GD; Stasiewicz S; French JE Toxicol Pathol; 1997; 25(6):533-40. PubMed ID: 9437796 [TBL] [Abstract][Full Text] [Related]
6. Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Hulla JE; French JE; Dunnick JK Toxicol Sci; 2001 Apr; 60(2):264-70. PubMed ID: 11248138 [TBL] [Abstract][Full Text] [Related]
7. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. French J; Storer RD; Donehower LA Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of cytotoxicity, cell proliferation, and genotoxicity induced by p-cresidine in hetero- and nullizygous transgenic p53 mice. Delker DA; Yano BL; Gollapudi BB Toxicol Sci; 2000 Jun; 55(2):361-9. PubMed ID: 10828268 [TBL] [Abstract][Full Text] [Related]
9. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination. Boley SE; Anderson EE; French JE; Donehower LA; Walker DB; Recio L Cancer Res; 2000 Jun; 60(11):2831-5. PubMed ID: 10850423 [TBL] [Abstract][Full Text] [Related]
10. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Ozaki K; Sukata T; Yamamoto S; Uwagawa S; Seki T; Kawasaki H; Yoshitake A; Wanibuchi H; Koide A; Mori Y; Fukushima S Cancer Res; 1998 Sep; 58(17):3806-11. PubMed ID: 9731488 [TBL] [Abstract][Full Text] [Related]
11. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551 [TBL] [Abstract][Full Text] [Related]
12. Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model. Petruska JM; Frank DW; Freeman GB; Evans EW; MacDonald JS Toxicol Pathol; 2002; 30(6):696-704. PubMed ID: 12512871 [TBL] [Abstract][Full Text] [Related]
13. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Hegi ME; Söderkvist P; Foley JF; Schoonhoven R; Swenberg JA; Kari F; Maronpot R; Anderson MW; Wiseman RW Carcinogenesis; 1993 May; 14(5):803-10. PubMed ID: 8504472 [TBL] [Abstract][Full Text] [Related]
14. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus. French JE IARC Sci Publ; 2004; (157):271-87. PubMed ID: 15055301 [TBL] [Abstract][Full Text] [Related]
16. Demonstration of ras and p53 gene mutations in carcinomas in the forestomach and intestine and soft tissue sarcomas induced by N-methyl-N-nitrosourea in the rat. Matsumoto K; Iwase T; Hirono I; Nishida Y; Iwahori Y; Hori T; Asamoto M; Takasuka N; Kim DJ; Ushijima T; Nagao M; Tsuda H Jpn J Cancer Res; 1997 Feb; 88(2):129-36. PubMed ID: 9119740 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxybutyl)nitrosamine. Yamamoto S; Min W; Lee CC; Salim EI; Wanibuchi H; Sukata T; Fukushima S Cancer Lett; 1999 Jan; 135(2):137-44. PubMed ID: 10096421 [TBL] [Abstract][Full Text] [Related]
18. Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Hulla JE Toxicol Sci; 2001 Dec; 64(2):281-2. PubMed ID: 11719711 [No Abstract] [Full Text] [Related]
19. Mutation and altered expression of p53 genes in experimental rat bladder tumor cells. Jones RF; Matuszyk J; Debiec-Rychter M; Wang CY Mol Carcinog; 1994 Feb; 9(2):95-104. PubMed ID: 8142014 [TBL] [Abstract][Full Text] [Related]
20. Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas. Kakinuma S; Nishimura M; Kubo A; Nagai JY; Amasaki Y; Majima HJ; Sado T; Shimada Y Mutat Res; 2005 May; 572(1-2):132-41. PubMed ID: 15790496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]